Natural polyphenols in ulcerative colitis: preclinical mechanisms of action and therapeutic potential

Chengu Niu1, Jing Zhang2, Patrick I Okolo3

  • 1Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY, USA.

Insights

Natural polyphenols show promise for treating ulcerative colitis (UC) by reducing inflammation and modulating gut bacteria. Further research supports their potential as novel therapeutic agents for UC management.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Natural Products Chemistry

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory condition with limited therapeutic options.
  • Current treatments offer moderate efficacy, necessitating novel therapeutic strategies.
  • Natural polyphenols have shown potential in preclinical and some clinical studies for UC.

Purpose of the Study:

  • To review evidence supporting the therapeutic potential of natural polyphenols in ulcerative colitis.
  • To discuss the mechanisms of action of natural polyphenols in UC.
  • To highlight the role of gut microbiota as a target for polyphenol therapy.

Main Methods:

  • Review of in vivo studies.
  • Analysis of limited clinical trial data.
  • Examination of proposed mechanisms of action.

Main Results:

  • Natural polyphenols demonstrate therapeutic potential in preclinical and clinical settings for UC.
  • Key mechanisms include anti-inflammatory and antioxidant effects.
  • Modulation of gut microbiota is a significant therapeutic target.

Conclusions:

  • Natural polyphenols are promising candidates for ulcerative colitis therapy.
  • Multiple mechanisms contribute to their efficacy, including immune modulation and barrier enhancement.
  • Targeting the gut microbiota is a key aspect of polyphenol-based UC treatment.

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
459
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
880
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
622